Paris-Sofinnova Partners, a European venture capital firm specialized in life sciences, announced the successful initial public offering (IPO) of Avantium, which raised €103-million on Euronext Amsterdam and Euronext Bruxelles. The funds will be used to further commercialize Avan-tium's inventions into viable production processes, Sofinnova noted. Sofinnova Capital VI remains the main shareholder following the IPO.
展开▼
